Loading
Latest filing published 10 Aug 2026 for Enanta Pharmaceuticals INC, €17k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Scott T. Rottinghaus in Enanta Pharmaceuticals Inc. The record holds 12 filings, for trades running from 8 August 2022 to 8 August 2026.
No open-market purchase appears, only 4 sales worth €81k. Other entries cover 8 share grants.
The latest filing, published on 10 August 2026, reports a share grant of €17k in Enanta Pharmaceuticals Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations